Top Pharmaceutical Companies in Boston, MA (130)
Who We Are Chewy is where pet parents find everything they need for life with pets, from food to fun to pharmacy. We make pet care easier, more informed, and more joyful through fast, reliable delivery and award-winning 24/7 Customer Care, including access to pet health support when it’s needed. Founded in 2011, Chewy combines the convenience of online shopping with...
Chewy's Top Stability & Growth Strengths
Customer Loyalty & Retention: Autoship accounts for the vast majority of sales (over four-fifths) and is growing faster than total revenue, indicating a sticky, recurring base and higher retention. Evidence includes Autoship representing ~83% of FY2025 net sales and ~84.6% in Q2 FY2026 with high single‑digit to double‑digit growth.
Profitability: Operating metrics show expanding earnings power, with adjusted EBITDA up materially and margins improving alongside strong free cash flow. Observations include FY2025 adjusted EBITDA growth of ~26% with margin expansion and additional year‑over‑year gains reported in 1H FY2026.
Strong Market Position & Advantage: Chewy is characterized as the largest U.S. pet e‑tailer and a leading online pet‑supplies platform by GMV and digital presence, underpinning durable scale advantages. Multiple summaries highlight leadership in online pet retail, substantial Autoship penetration, and strong digital search share versus specialty peers.
Formation Bio is a tech-driven pharma company differentiated by radically more efficient drug development. Formation Bio has built a technology platform that optimizes all aspects of drug development, enabling more efficient trial design, faster trial completion, and higher quality trial data capture. Formation Bio acquires clinical-stage drugs from pharma and biotech and develops them faster and more efficiently, unlocking greater...
Formation Bio's Top Stability & Growth Strengths
Investor Backing & Capital Strength: Capital raising has accelerated, including a $372M Series D in 2024 with total funding reported in the hundreds of millions to expand the pipeline and AI platform. Valuation has stepped up from roughly $1.04B (2021) to about $1.48B post‑money (2024), signaling strengthened private‑market positioning.
Strategic Partnerships: Partnerships are expanding, highlighted by a collaboration with Sanofi and OpenAI to build AI software for drug development and increased business‑development capacity via Entrepreneurs in Residence. Engagements with large pharma partners, including Sanofi, underscore growing external validation and deal flow.
Product Line Growth: The pipeline is broadening through multiple in‑licenses—such as an anti‑CD226 program, a CNS‑penetrant TYK2 inhibitor, and a miR‑124 activator—and progression to first‑in‑human dosing of BLKR201 in 2026. Stated plans to reach 10–15 assets over 3–5 years align with recent portfolio expansion and clinical advancement.
Schrödinger is a leading provider of advanced molecular simulations and enterprise software solutions and services for pharmaceutical, biotechnology, and materials science research. The predictive power of Schrödinger's software allows scientists to accelerate their research and development, reduce research costs, and make novel discoveries.
Schrödinger, Inc.'s Top Stability & Growth Strengths
Strong Revenue Growth: Recent results indicate total revenue increased year over year in 2025 and continued to rise in the latest reported quarter. Guidance and quarterly updates point to ongoing top-line expansion even as mix shifts occur.
Resilient & Sustainable Growth: Underlying annual contract value expanded and accelerated in 2026, with management indicating continued growth despite the transition to hosted licensing. This suggests the core subscription base is strengthening even when reported revenue timing varies.
Diversified Revenue Streams: Growth is visible in both the software business and the milestone-driven drug discovery segment. The latter stepped up meaningfully in recent periods, complementing steady software momentum.
For nearly a decade, KalVista Pharmaceuticals has been focused on addressing the critical unmet needs of those living with hereditary angioedema (HAE). With more than 250 employees worldwide, we leverage our team’s vast knowledge and expertise across all aspects of research, development, and commercialization to redefine the future of HAE treatment and advance global care for those who need it most.
At Lonza, we enable A Healthier World by supporting our healthcare customers on the path to commercialization. Our community of 16,000 talented employees work across a global network of more than 30 sites to deliver for our customers across the pharma, biotech and nutrition markets.
ArisGlobal is transforming the way today’s most successful life sciences companies develop breakthroughs and bring new products to market. Our end-to-end drug development technology platform, LifeSphere®, integrates our proprietary cognitive computing engine to automate all core functions of the drug development lifecycle. Designed with deep expertise and a long-term perspective that spans more than 30 years, LifeSphere® boosts efficiency, ensures...
.png)
Parexel is among the world’s largest clinical research organizations (CROs), providing the full range of Phase I to IV clinical development services to help life-saving treatments reach patients faster. Leveraging the breadth of our clinical, regulatory and therapeutic expertise, our team of more than 21,000 global professionals collaborates with biopharmaceutical leaders, emerging innovators and sites to design and deliver clinical...
Parexel's Top Stability & Growth Strengths
Strong Market Position & Advantage: Feedback suggests Parexel is consistently viewed as a top-tier, full-service CRO, reinforced by repeated industry awards and strong site collaboration recognition. These signals indicate competitive strength in winning and delivering complex global programs.
Strategic Partnerships: Feedback suggests multi-year collaborations to embed advanced analytics and AI (e.g., Palantir and other AI initiatives) are intended to improve trial efficiency and differentiation. Such partnerships underscore continued investment in modernization and execution.
Market Expansion: Feedback suggests the company opened a new global headquarters in Raleigh and continues to reference a 20,000+ to 24,000+ global workforce, indicating operational scaling. Physical expansion and ongoing hiring activity support broader delivery capacity across regions.
Mariana Oncology, a Novartis company, is a fully integrated next generation radiopharmaceutical company that brings together experts in ligand discovery, radiochemistry, radiobiology and oncology translational and clinical research in order to build a pipeline across a range of solid tumor types. Our mission at Mariana is to discover and develop safe, effective, and highly targeted radiopharmaceuticals.
For 130 years, Merck, known as MSD outside of the United States and Canada, has been inventing for life, bringing forward medicines and vaccines for many of the world’s most challenging diseases in pursuit of our mission to save and improve lives. We demonstrate our commitment to patients and population health by increasing access to health care through far-reaching policies,...
Merck's Top Stability & Growth Strengths
Strong Market Position & Advantage: Merck holds a clear leadership position, anchored by Keytruda—the world’s top‑selling cancer medicine at $31.7B in 2025—and strong standings in vaccines and overall scale among global pharmas. Animal health also ranks among top players, reinforcing breadth across key healthcare markets.
Innovation-Driven Growth: A broad late‑stage pipeline and scientific presence (100+ ASCO 2026 abstracts across 25+ tumor types) span oncology, vaccines, infectious disease, and cardiometabolic areas. Ongoing label expansions and new formats like subcutaneous Keytruda (including U.S. Keytruda Qlex) are adding growth vectors.
Diversified Revenue Streams: Sales draw from oncology, vaccines (e.g., Gardasil over $10.7B in 2025), hospital acute care, and a growing animal health segment. Newer launches and alliances (e.g., Winrevair, IDVYNSO, and partnered oncology assets) are contributing to mix.
AstraZeneca is a global, science-led, patient-focused biopharmaceutical company committed to excellence in the research, development, and commercialization of prescription medicines. With approximately 90,000 employees across 85 countries, the company aims to unlock the power of science to deliver innovative medicines that transform patient outcomes and improve healthcare for people, society, and the planet worldwide.
OCB Eye Health Services provided patients with medical laser and surgical eye care of the highest quality. In addition to eye examinations, our ophthalmologists provide care in the following specialties: cataract, glaucoma, cornea, diseases of the retina, orbital plastics, pediatrics, LASIK refractive surgery and eye trauma. Our staff of 30 ophthalmologists and 13 optometrists care for over 165,000 patients each...
At Synaptiq Health, we are deeply passionate about advancing life-changing therapies and services. As a collective of specialised agencies, including Emotive, Initiate, and Beyond PR, we bring together unparalleled expertise across Medical Communications, Market Access & HEOR, and PR & Advocacy. Our dedicated teams partner with top global pharmaceutical, biopharma, and biotechnology companies, as well as influential medical societies and health...
Invivyd is a biopharmaceutical company on a mission to rapidly and perpetually deliver antibody-based therapies that protect vulnerable people from the devastating consequences of circulating viral threats, beginning with SARS-CoV-2. Invivyd’s technology works at the intersection of evolutionary virology, predictive modeling, and antibody engineering, and is designed to identify high-quality, long-lasting antibodies with the potential to resist viral escape. The...
Kalderos is a data infrastructure and analytics company that’s solving challenges around drug discounts in the U.S. healthcare system. Through platform technology and big data, our team is delivering smart solutions that enable healthcare stakeholders to collaborate with greater transparency and trust. We’re passionate about our mission to take on the most stubborn challenges in healthcare. We also know that...
Kalderos's Top Stability & Growth Strengths
Strong Revenue Growth: Revenue is reported to have more than doubled in 2021 and again in 2022, indicating rapid topline acceleration. Customer counts also doubled over the same period, reinforcing strong adoption momentum.
Investor Backing & Capital Strength: Capital raises total roughly $76.3M across multiple years, including $26.4M sold in a January 2025 offering recorded by the SEC. This sustained access to funding points to continued investor confidence late in the company’s private lifecycle.
Product Line Growth: The platform expanded beyond its original scope into MDRP Discount Monitoring, Commercial Discount Monitoring, and 340B Pay to meet demand. The Commercial Discount Monitoring product alone cites 8 customers, 16M+ claims processed, and data from 37 PBMs.
Syner-G is a strategic biopharma product development and delivery partner dedicated to accelerating breakthrough science and the delivery of life-enhancing therapies to more patients. Utilizing expertise, insight, consulting, and management skills, the company supports a diverse range of clients and projects, guiding organizations from the most critical phases of drug discovery and approval through to successful commercialization, ensuring meaningful real-world...
The AMR Action Fund is a groundbreaking VC fund that enables breakthroughs in the development of antibiotics, anti-fungals, and other antimicrobials. We invest in companies developing innovative treatments for priority drug-resistant pathogens and advocate for market reforms and policy solutions to change how society values these lifesaving drugs
SHYFT Analytics is an industry leader in cloud data management and mobile analytics for the global life sciences industry. SHYFT is used by pharmaceutical, biotech, medical device and other healthcare leaders from around the globe and across thousands of users. With over 10 years innovating in life sciences, SHYFT’s industry cloud platform is leading the transformation in healthcare and helping...
Headquartered in Dedham, Mass., AliMed is a specialty medical supplies manufacturer and distributor with on-site customization capabilities and a vast portfolio of healthcare products designed to improve patient outcomes and experiences. Celebrating 50 years of serving patient needs spanning “hospital to home,” AliMed has built its long history and strong reputation on responsiveness, exceptional customer service, and high-quality offerings. Visit AliMed.com...
Advancing knowledge to improve lives.™ We are a global strategic partner with decades of experience across the entire life sciences product lifecycle. We excel in providing our clients with unique insights and efficiencies to support them in their journey to improve health outcomes and ultimately the quality of people’s lives. By connecting our full suite of products and services from scientific...
EdenRoc Sciences is a privately-held biotechnology company formed to cultivate world-class life sciences start-up companies. EdenRoc specializes in enabling efficient translation of top tier academic and government science into technologies which provide novel and cutting-edge research tools, diagnostics, and pharmaceuticals.
